- Home
- » Tags
- » Kyowa Hakko Kirin
Top View
- Partnering Data As of November 2018
- Japan Board Index 2020 5 Key Findings
- Annual Report 2017 for the Year Ended December 31, 2017
- News Release
- ΧΏΡΑ ΤΜΉΜΑ Ιαπωνία Plants Or Establishments Manufacturing
- Approval for Additional Indication of Pheochromocytoma for Dacarbazine Injection 100
- Integrated Report (Year Ended March 2020)
- Disclosure Award
- 1 Notice of Convocation of the 98Th Ordinary General Meeting of Shareholders Please Be Advised That the 98Th Ordinary General Me
- Japan's Biggest Biotech
- Home-Measured Blood Pressure Is Associated with Handgrip Strength in Patients with Type 2 Diabetes: the KAMOGAWA-HBP Study
- CDP Japan Water Security Report 2018
- Japan Voting Report January - March 2018
- Biol. Pham. Bull. Regular Article Analytical Biochemistry Comparison of Antibody Molecules Produced from Two Cell Lines With
- Annual Report 2019 for the Year Ended December 31, 2019
- 400 Code Market Divison Issue the FFW Ratio Following Cap
- Integrated Reporting to Support Sustainable Growth in Japan
- November 4, 2009
- Lymphoma: a Single-Arm, Open-Label, Phase 2 Study
- News Release
- Correction To: Japanese Clinical Practice Guideline for Diabetes 2016
- ICMJE Form for Disclosure of Potential Conflicts of Interest
- RELAY Subgroup Analyses by EGFR Ex19del and Ex21l858r Mutations For
- (12) Patent Application Publication (10) Pub. No.: US 2014/0046038A1 SHHARA (43) Pub
- [BA] COUNTRY [BA] SECTION [Ba] Japan
- Japan Market Outlook- 13 July 2021
- THE HISTORY of CHEMISTRY in JAPAN and AROUND the WORLD - Focusing on Invention, Discovery, Commercialization, and the Founding of Major Companies
- CFD Type IB Symbol Product Description Symbol Currency Share
- Kyowa Hakko Kirin Annual Report 2009 All
- Recent Patents in Antibody Engineering
- Japan Affiliate) Venue: Tower Hall Funabori Beyond the New Horizon: Implementation of the Global Standard 〒134-0091 4-1-1 Funabori Edogaw-Ku Tokyo
- Integrated Report (Year Ended March 2020)
- "JPX-Nikkei Index 400"
- Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression
- Annual Report 2015 for the Year Ended December 31, 2015
- Annual Report 2009